Overall Survival Benefit Up for Pyrotinib + Capecitabine in HER2-Positive Breast Cancer

For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, pyrotinib plus capecitabine offers an overall survival benefit.

Related Keywords

China ,Portugal ,Shanghai ,Peking ,Beijing ,Lisbon ,Lisboa ,Chinese ,Binghe Xu ,Union University ,Fudan University Cancer Hospital ,Chinese Academy Of Medical Sciences ,Breast Cancer Seventh International Consensus Conference ,Jiangsu Hengrui Pharmaceuticals ,Healthday News ,Chinese Academy ,Medical Sciences ,Peking Union University ,